Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Vicagrel vs Clopidogrel in Healthy Subjects Stratified by CYP2C19 Genotype
NCT03942458Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicagrel in acute coronary syndrome (ACS) and thrombosis (2 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Peak Plasma Concentration at Day 7, Area under the plasma concentration versus time curve at Day 7 and 3 more. Started Apr 2019; status: completed.
02
Drugs
vicagrel
03
Conditions
acute coronary syndrome (ACS)thrombosis
Beyond the preview
Go deeper on NCT03942458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942458.